Trinity Biotech
TRIB
19 hedge funds and large institutions have $379K invested in Trinity Biotech in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 4 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
0.03% less ownership
Funds ownership: 0.19% → 0.16% (-0.03%)
10% less funds holding
Funds holding: 21 → 19 (-2)
36% less capital invested
Capital invested by funds: $589K → $379K (-$209K)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HAIM
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
+$77.1K |
| 2 |
WN
Williams & Novak
Westlake Village,
California
|
+$20.3K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$16.6K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$2.35K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$2.17K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YAG
Yorkville Advisors Global
Mountainside,
New Jersey
|
-$122K |
| 2 |
VF
Virtu Financial
New York
|
-$14K |
| 3 |
Renaissance Technologies
New York
|
-$9.63K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$2.5K |
| 5 |
TCM
Triumph Capital Management
Denver,
Colorado
|
-$542 |
TRIB Hedge Fund Activity: Q2 2026 in Review
19 of the 8,300 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q2 2026, worth a combined $379K — down 36% from $589K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of TRIB and 2 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 5 added.
The largest buyer was Hunter Associates Investment Management, adding an estimated $77.1K. The largest seller was Yorkville Advisors Global, exiting entirely with an estimated $122K sold.
- 19 institutional investors held Trinity Biotech (TRIB) as of Q2 2026, down from 21 in Q1 2026.
- Funds reported $379K of Trinity Biotech stock for Q2 2026, down 36% quarter-over-quarter.
- 2 funds opened new Trinity Biotech positions in Q2 2026 and 4 closed out, a net change of -2 holders.
- The largest Trinity Biotech buyer in Q2 2026 was Hunter Associates Investment Management, an estimated $77.1K added.
- The largest Trinity Biotech seller in Q2 2026 was Yorkville Advisors Global, an estimated $122K sold.
Based on aggregated 13F filings for Q2 2026.